Navigation Links
FDA Warns of Painkiller Mix-Up at Nebraska Plant
Date:1/9/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, Jan. 9 (HealthDay News) -- The U.S. Food and Drug Administration issued a warning on Monday that some narcotic prescription painkillers made at a Nebraska plant may have been mixed up with some over-the-counter medicines packaged at the same facility.

"We issued a public health advisory to health care professionals and patients about a potential problem with opioid products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska, site," Dr. Edward Cox, director of the FDA's Office of Antiviral Products in the Office of New Drugs at the Center for Drug Evaluation and Research, said during a morning news conference.

On Sunday, Novartis issued a recall for some over-the-counter medications made at the same plant. These included Excedrin, NoDoz, Bufferin and Gas-X, Cox said.

"Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended, or receiving an unintended ingredient," Novartis said in the Sunday news release. "This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient."

Cox noted that it is possible, but unlikely, that these over-the-counter medications and prescription opioid painkillers could be mixed up together, although "we are still looking into this."

The narcotic painkillers in question include Opana, Percocet, Endocet and Zydone.

The problem occurred because the machinery used to package these products can retain pills from a previous packaging run, Cox explained.

"This could result in an incorrect pill ending up in the bottle of another product," Cox explained. "The likelihood of this occurring in medication dispensed to patients is estimated to be low."

Endo Pharmaceuticals officials claim they know of only three such mix-ups since 2009, Cox said. Moreover, the company is not aware of any patients who took the wrong pills or of "any adverse effects attributable to a product mix-up," Cox added.

The company and the FDA are providing information to help patients identify any stray pills. "We are asking patients to check their medicines to identify any pills of a different size, shape or color from their regular medicine," Cox said.

If any pills differ from the rest in the bottle, patients should stop taking their medicine and take the bottle to their pharmacist, Cox said.

Until these problems are fixed, manufacturing at the plant will remain shut down, the company said. Customers can call 1-888-477-2403 Monday to Friday, from 9 a.m. to 8 p.m., while patients can call Endo Pharmaceuticals' call center at 1-800-462-3636.

During the closure, there may be a shortage of certain painkillers, but several alternatives are available, the FDA noted.

Cox said that the agency decided not to issue a recall because of the small chance of a patient taking the wrong pill and the need for these prescription painkillers.

"After carefully considering the public health risks, [the] FDA does not believe that a recall of Endo's opioid analgesic product is warranted," Cox said.

Cox added that this plant has had problems in the past, and that the FDA's investigation is ongoing.

More information

For more on the painkiller mix-up, visit the U.S. Food and Drug Administration.

SOURCES: Jan. 9, 2012, press conference with: Edward Cox, M.D., director, Office of Antiviral Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Jan. 8, 2012, press release, Novartis Consumer Health


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Diet Still Has Too Much Salt, CDC Warns
2. Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns
3. The Hype on Hypoallergenic Dogs Is Just That, Study Warns
4. CDC Warns Against Exposure to Mad Cow-Like Brain Diseases
5. Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns
6. Research Warns of Overuse of Powerful Class of Antibiotics
7. Snow Shoveling Injuries Affect Old and Young, Expert Warns
8. Dont Let the Bedbugs Bite, Allergist Warns
9. Study Warns of Risks for Early Dialysis
10. Bone Drugs Linked to Rare Fractures, FDA Warns
11. Don't Drink and Drive on Fourth of July Weekend, Washington, D.C., Attorney Warns
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Warns of Painkiller Mix-Up at Nebraska Plant
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: